Development of a new therapy for prostate cancer by the fusion of the thermotherapy mediated by magnetic field and the immunotherapy
| Project/Area Number |
24592403
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Nagoya City University |
|---|
Principal Investigator |
KAWAI Noriyasu 名古屋市立大学, 医学(系)研究科(研究院), 講師 (20254279)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KOBAYASHI Takeshi 中部大学, 生物機能開発研究所, 教授 (10043324)
KOHRI Kenjiro 名古屋市立大学, その他の部局, 学長 (30122047)
TOZAWA Keiichi 名古屋市立大学, 大学院医学研究科, 准教授 (40264733)
SASAKI Shoichi 名古屋市立大学, 大学院医学研究科, 准教授 (50225869)
NAIKI Taku 名古屋市立大学, 大学院医学研究科, 研究員 (50551272)
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2014: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2013: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2012: ¥2,990,000 (Direct Cost: ¥2,300,000、Indirect Cost: ¥690,000)
|
|---|
| Keywords | 温熱治療 / 温熱免疫 / 前立腺癌 / ナノテクノロジー / 磁場 / がん免疫 / 免疫治療 |
|---|
| Outline of Final Research Achievements |
We developed several years ago new cancer thermotherapy “MCL Heat Therapy”, which is based on the particular character of the magnetite (Fe3O4). The character is generating heat by irradiation of alternative magnetic field. We performed basic research for the purpose of developing new therapy to treat both primary and metastatic lesion by which MCL Heat Therapy and cancer immunotherapy are fused. In vitro, we could not find the enhancement of tumor antigen from prostate cancer cell by heat therapy. However, in vitro, helper T cell and cytotoxic T cell were appeared in tumor tissue by MCL Heat Therapy.
Under the acceptance of Institutional Review Bore of our university, new Heat Therapy with inductive heating machine RF-8 and local injection of MCL was performed for three patients. There were no adverse events.
|
Report
(4 results)
Research Products
(3 results)
